Psychopharmacology

, Volume 192, Issue 4, pp 479–487

Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study

  • Daniela Eser
  • Cornelius Schüle
  • Thomas Baghai
  • Anette Floesser
  • Axel Krebs-Brown
  • Michaela Enunwa
  • Stephan de la Motte
  • Rolf Engel
  • Klaus Kucher
  • Rainer Rupprecht
Original Investigation

DOI: 10.1007/s00213-007-0738-7

Cite this article as:
Eser, D., Schüle, C., Baghai, T. et al. Psychopharmacology (2007) 192: 479. doi:10.1007/s00213-007-0738-7

Abstract

Rationale

Experimental panic induction with cholecystokinin-tetrapeptide (CCK-4) has been established as a model to study the pathophysiology of panic disorder and might serve as a tool to asses the antipanic potential of novel anxiolytic compounds. However, assessment of CCK-4-induced panic does not follow consistent rules.

Objectives

To provide a basis for the use of the CCK-4 model in proof-of-concept studies, we investigated CCK-4-induced panic according to different criteria in 85 healthy volunteers who underwent a CCK-4 bolus injection.

Methods

We assessed panicker/non-panicker ratios according to different panic criteria and explored whether differences in cardiovascular and neuroendocrine responses to CCK-4 paralleled subjective panic responses. Subjective panic responses were measured with the Acute Panic Inventory (API) and the Panic Symptom Scale (PSS). Heart rate, blood pressure, adrenocorticotropic hormone (ACTH) and cortisol were assessed concomitantly.

Results

The API-derived panic rate was 10.6% higher than that derived from the PSS. CCK-4 induced an increase in heart rate, systolic blood pressure and ACTH/cortisol plasma levels, which did not differ between panickers and non-panickers.

Conclusions

The panic criterion applied appears to be of major importance for the panic rate achieved, whereas CCK-4-induced cardiovascular and hormonal alterations are not valuable as an objective “read out”. The CCK-4 challenge might serve as a useful model to study putative anxiolytic effects of novel compounds during the early phase of drug development if the challenge procedure is carried out according to strictly comparable conditions.

Keywords

CCK-4Panic disorderAnxietyChallenge paradigmProof-of-concept

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Daniela Eser
    • 1
  • Cornelius Schüle
    • 1
  • Thomas Baghai
    • 1
  • Anette Floesser
    • 2
  • Axel Krebs-Brown
    • 3
  • Michaela Enunwa
    • 4
  • Stephan de la Motte
    • 4
  • Rolf Engel
    • 1
  • Klaus Kucher
    • 2
  • Rainer Rupprecht
    • 1
  1. 1.Department of Psychiatry and PsychotherapyLudwig-Maximilian-UniversityMunichGermany
  2. 2.Exploratory Clinical DevelopmentNovartis Pharma AGBaselSwitzerland
  3. 3.BiostatisticsNovartis Pharma AGBaselSwitzerland
  4. 4.Harrison Clinical Research InstituteMunichGermany